Lipopeptide Mimics for Immune Modulation ID: 2013-033
A novel approach to modulate immune responses and regulate inflammation using lipopeptide mimics.
Photo by starlineart - stock.adobe.com
Technology Overview
This technology involves the creation of lipopeptide mimics (LPMs) that promote TLR2/6 heterodimer formation to regulate inflammation, particularly in the gastrointestinal tract. These mimics are designed to be resistant to proteases and lipases, ensuring their stability and function within the body. The invention has shown promise in treating autoimmune and inflammatory diseases, and as vaccine adjuvants, through the modulation of cytokine responses.
Key Advantages
- Stability in the gastrointestinal tract due to resistance to proteases and lipases
- Specific promotion of TLR2/6 heterodimer formation, targeting inflammation regulation
- Potential to treat a variety of autoimmune and inflammatory diseases
- Capability to serve as adjuvants in vaccine formulations
- Supported by experimental data demonstrating the production of anti-inflammatory cytokines
Problems Addressed
- Challenges in regulating inflammation in the gastrointestinal tract
- Limited treatment options for autoimmune and inflammatory diseases
- Need for more effective vaccine adjuvants
- Difficulty in maintaining stability of therapeutic compounds within the gastrointestinal environment
Market Applications
- Treatment of inflammatory bowel disease and coeliac disease
- Prevention of cancer associated with chronic inflammation
- Enhancement of vaccine efficacy through improved adjuvant formulations
Additional Information
Technology ID: 2013-033
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 13 May, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report